New antibody cocktail takes on tough ovarian cancers

NCT ID NCT04590326

Recruiting now Disease control Sponsor: Regeneron Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental drug called REGN5668, alone or combined with other drugs, in people with ovarian, fallopian tube, peritoneal, or endometrial cancer. The trial has two parts: first to find the safest dose, then to see if the drug shrinks tumors. About 612 participants will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: REGN5668 (a bispecific antibody) alone or combined with cemiplimab, fianlimab, ubamatamab, or sarilumab
What this could lead to: If successful, this could point toward a new treatment option for ovarian and related cancers that have not responded to standard therapy.
What could go wrong: This is an early-phase trial (Phase 1/2) focused on safety and dosing, so it is not yet known if the drug combination will effectively shrink tumors. Side effects may be significant, and the results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endometrial cancer endometrium neoplasm fallopian tube cancer fallopian tube neoplasm ovarian cancer primary peritoneal carcinoma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ENDOMETRIAL CANCER FALLOPIAN TUBE CANCER OVARIAN CANCER PRIMARY PERITONEAL CANCER

Contacts and locations

Locations

Centre Francois Baclesse (CFB)
RECRUITING

Caen, Normandy, 14076, France
Centre Georges Francois Leclerc
RECRUITING

Dijon, Bourgogne-Franche-Comté, 21000, France
Chao Family Comprehensive Cancer Center
RECRUITING

Orange, California, 92868, United States
City of Hope Comprehensive Cancer Center
RECRUITING

Duarte, California, 91010, United States
Ciudad Universitaria
RECRUITING

Madrid, 28040, Spain
Dana Farber Cancer Institute Brookline Avenue
RECRUITING

Boston, Massachusetts, 02215, United States
H. Lee Moffitt Cancer Center
COMPLETED

Tampa, Florida, 33612, United States
Hopital Lyon Sud
RECRUITING

Pierre-Bénite, Auvergne-Rhône, 69310, France
Hospital Clinico Universitario Santiago de Compostela
RECRUITING

Santiago de Compostela, A Coruna, 15706, Spain
Hospital Universitario 12 de Octubre Universidad Complutense de Madrid UCM
RECRUITING

Madrid, 28041, Spain
Hospital Universitario Fundacion Jimenez
RECRUITING

Madrid, 28040, Spain
Institut Bergonie
RECRUITING

Bordeaux, New Aquitaine, 33076, France
Institut Catala dOncologia Girona
RECRUITING

Girona, 17007, Spain
Institut Gustave Roussy
RECRUITING

Villejuif, 94805, France
Karmanos Cancer Institute
RECRUITING

Detroit, Michigan, 48201, United States
Massachusetts General Hospital
RECRUITING

Boston, Massachusetts, 02114, United States
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States
Perelman School of Medicine at the University of Pennsylvania
RECRUITING

Philadelphia, Pennsylvania, 19104, United States
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
RECRUITING

Chicago, Illinois, 60611, United States
Seattle Cancer Care Alliance at South Lake Union - G3630
RECRUITING

Seattle, Washington, 98109, United States
The City of Hope Orange County Lennar Foundation Cancer Center
RECRUITING

Irvine, California, 92618, United States
The Ohio State University Wexner Medical Center
RECRUITING

Columbus, Ohio, 43210, United States
Universitair Ziekenhuis Leuven
RECRUITING

Leuven, Vlaams-Brabant, 3000, Belgium
University of Chicago Medical Center
RECRUITING

Chicago, Illinois, 60637, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.